Advertisement
Research Article

Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature

  • Alexander C. Tsai equal contributor mail,

    equal contributor Contributed equally to this work with: Alexander C. Tsai, Nicholas Z. Rosenlicht

    nicholas.rosenlicht@ucsf.edu

    Affiliation: Robert Wood Johnson Health and Society Scholars Program, Harvard University, Cambridge, Massachusetts, United States of America

    X
  • Nicholas Z. Rosenlicht equal contributor,

    equal contributor Contributed equally to this work with: Alexander C. Tsai, Nicholas Z. Rosenlicht

    Affiliation: Department of Psychiatry, University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America

    X
  • Jon N. Jureidini,

    Affiliation: Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia, Australia

    X
  • Peter I. Parry,

    Affiliation: Child and Adolescent Mental Health Service, Division of Mental Health, Flinders University, Adelaide, South Australia, Australia

    X
  • Glen I. Spielmans,

    Affiliation: Department of Psychology, Metropolitan State University, St. Paul, Minnesota, United States of America

    X
  • David Healy

    Affiliation: Department of Psychological Medicine, Cardiff University, Cardiff, Wales, United Kingdom

    X
  • Published: May 03, 2011
  • DOI: 10.1371/journal.pmed.1000434

About the Authors

Alexander C. Tsai
Robert Wood Johnson Health and Society Scholars Program, Harvard University, Cambridge, Massachusetts, United States of America
Nicholas Z. Rosenlicht
Department of Psychiatry, University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America
Jon N. Jureidini
Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia, Australia
Peter I. Parry
Child and Adolescent Mental Health Service, Division of Mental Health, Flinders University, Adelaide, South Australia, Australia
Glen I. Spielmans
Department of Psychology, Metropolitan State University, St. Paul, Minnesota, United States of America
David Healy
Department of Psychological Medicine, Cardiff University, Cardiff, Wales, United Kingdom

Corresponding Author

Email: nicholas.rosenlicht@ucsf.edu

Competing Interests

ACT receives salary support through the Robert Wood Johnson Foundation Health and Society Scholars Program. The Robert Wood Johnson Foundation's stated mission is to improve the health and health care of all Americans. NZR is a member of the National Physicians Alliance, a not-for-profit organisation whose stated primary goal is to restore physicians' primary emphasis on the core values of service, integrity, and advocacy. The National Physicians Alliance rejects funding from commercial health care interests and encourages its members to do the same. NZR, JNJ, and PIP are members of Healthy Skepticism, an international not-for-profit organisation whose stated aim is to improve health by reducing harm from misleading drug promotion; GIS joined Healthy Skepticism after this article was accepted for publication. GIS is a current shareholder (<$10,000) in a mutual fund, Vanguard Healthcare, that invests heavily in pharmaceutical companies. DH reports no links to pharmaceutical companies in the past 5 years. ACT is a former board member of the ethics committee, and former member, of the National Physicians Alliance. ACT and NZR are former members of No Free Lunch, a not-for-profit organisation whose stated mission was to encourage health care providers to practice medicine on the basis of scientific evidence rather than on the basis of pharmaceutical promotion. JNJ was engaged by the law firm of Baum, Hedlund, Aristei & Goldman to provide an independent analysis of the data in Glaxo SmithKline's Study 329 of paroxetine in adolescents. DH has been an expert witness in ten legal cases involving antidepressant medications and one case involving the patent on olanzapine (Zyprexa).

Author Contributions

ICMJE criteria for authorship read and met: ACT NZR JNJ PIP GIS DH. Agree with the manuscript's results and conclusions: ACT NZR JNJ PIP GIS DH. Designed the experiments/the study: ACT NZR. Analyzed the data: ACT NZR JNJ GIS DH. Collected data'did experiments for the study: ACT NZR. Wrote the first draft of the paper: ACT NZR. Contributed to the writing of the paper: ACT NZR JNJ PIP GIS DH. Contributed to the concept and design of the paper and first draft: PIP.